Aethlon Medical (NASDAQ:AEMD) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Rating) in a note issued to investors on Friday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, Maxim Group cut Aethlon Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, November 15th.

Aethlon Medical Trading Down 2.2 %

Aethlon Medical stock opened at $0.48 on Friday. The stock has a market cap of $8.01 million, a P/E ratio of -0.62 and a beta of 0.96. The stock has a 50 day moving average of $0.38 and a 200-day moving average of $0.73. Aethlon Medical has a 52 week low of $0.23 and a 52 week high of $2.46.

Aethlon Medical (NASDAQ:AEMD – Get Rating) last released its earnings results on Monday, November 14th. The medical equipment provider reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, equities analysts predict that Aethlon Medical will post -0.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aethlon Medical

Large investors have recently added to or reduced their stakes in the company. Natixis bought a new position in Aethlon Medical during the second quarter worth $28,000. Buckingham Strategic Partners bought a new stake in Aethlon Medical in the third quarter valued at $29,000. Two Sigma Investments LP bought a new stake in Aethlon Medical in the third quarter valued at $32,000. Renaissance Technologies LLC bought a new stake in Aethlon Medical in the third quarter valued at $36,000. Finally, Citadel Advisors LLC bought a new stake in Aethlon Medical in the third quarter valued at $72,000. 11.86% of the stock is currently owned by institutional investors.

About Aethlon Medical

(Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.